Publication:
Up and downgrading in single intermediate-risk positive biopsy core prostate cancer

Thumbnail Image

Organizational Units

Program

KU-Authors

KU Authors

Co-Authors

Hoeh, B.
Flammia, R.
Hohenhorst, L.
Sorce, G.
Chierigo, F.
Tian, Z.
Saad, F.
Gallucci, M.
Briganti, A.
Terrone, C.

Advisor

Publication Date

Language

English

Journal Title

Journal ISSN

Volume Title

Abstract

Background: up- and/or downgrading rates in single intermediate-risk positive biopsy core are unknown. Methods: We identified single intermediate-risk (Gleason grade group (GGG) 2/GGG3) positive biopsy core prostate cancer patients (? cT2c and PSA ? 20 ng/mL) within the Surveillance, Epidemiology, and End Results (SEER) database (2010–2015). Subsequently, separate uni- and multivariable logistic regression models tested for independent predictors of up- and downgrading. Results: of 1,328 assessable patients with single core positive intermediate-risk prostate cancer at biopsy, 972 (73%) harbored GGG2 versus 356 (27%) harbored GGG3. Median PSA (5.5 vs 5.7; p = 0.3), median age (62 vs 63 years; p = 0.07) and cT1-stage (77 vs 75%; p = 0.3) did not differ between GGG2 and GGG3 patients. Of individuals with single GGG2 positive biopsy core, 191 (20%) showed downgrading to GGG1 versus 35 (4%) upgrading to GGG4 or GGG5 at RP. Of individuals with single GGG3 positive biopsy core, 36 (10%) showed downgrading to GGG1 versus 42 (12%) significant upgrading to GGG4 or GGG5 at RP. In multivariable logistic regression models, elevated PSA (10–20 ng/mL) was an independent predictor of upgrading to GGG4/GGG5 in single GGG3 positive biopsy core patients (OR:2.89; 95%-CI: 1.31–6.11; p = 0.007). Conclusion: in single GGG2 positive biopsy core patients, downgrading was four times more often recorded compared to upgrading. Conversely, in single GGG3 positive biopsy core patients, up- and downgrading rates were comparable and should be expected in one out of ten patients.

Description

Source:

Prostate International

Publisher:

Elsevier

Keywords:

Subject

Biopsy, Gleason score, Prostate-specific antigen

Citation

Endorsement

Review

Supplemented By

Referenced By

Copy Rights Note

0

Views

0

Downloads

View PlumX Details